Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial). (2019)

First Author: Morrison EE

Attributed to: Confidence in Concept 2012 - Edinburgh funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2019.07.013

PubMed Identifier: 31311721

Publication URI: http://europepmc.org/abstract/MED/31311721

Type: Journal Article/Review

Volume: 46

Parent Publication: EBioMedicine

ISSN: 2352-3964